Skip to main content

May 2015, Vol 5, No 4

FDA-Approved Medications Used for the Treatment of Leukemia

May 2015, Vol 5, No 4

The following sections will assist healthcare professionals and payers by providing appropriate coding and billing information associated with the treatment of leukemia. Read More ›

Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting

By Lisa A. Raedler, PhD, RPh

May 2015, Vol 5, No 4

Trials Under Way for Patients with Melanoma

Clinical Trials Tracker

May 2015, Vol 5, No 4

Seven Steps to Finding the Right Financial Advisor

By W. Ben, Utley, CFP; Lawrence B. Keller, CFP, CLU, ChFC, RHU, LUTCF

Financial Management, Practice Management, Practice Management

May 2015, Vol 5, No 4

Rest in Peace, SGR

May 2015, Vol 5, No 4

Sunitinib Associated with Higher Costs Compared with Pazopanib in Patients with RCC

May 2015, Vol 5, No 4

Federal Government Outlines Stage 3 of Meaningful Use

By Rosemary Frei, MSc

May 2015, Vol 5, No 4

Waiting for the Carrot? It May Take a While

By Dawn Holcombe, MBA, FACMPE, ACHE

From the Editor

May 2015, Vol 5, No 4

The Nurse Practitioner’s Role in the Practice

By Peggy Barton, RN

Best Practices, Practice Management

May 2015, Vol 5, No 4

340B Rules Remain in Flux

By Rosemary Frei, MSc

May 2015, Vol 5, No 4

Page 1 of 2